Answers are grounded in this paper and cite their sources.
Targeted parallel reaction monitoring (PRM) mass spectrometry enables sensitive and reproducible glycan quantification, but data analysis for permethylated N-glycans currently relies on manual adaptation of proteomics tools such as Skyline combined with GlycoWorkbench for transition curation. This workflow requires extensive user intervention for fragment validation, isobaric disambiguation, and peak integration, limiting throughput and introducing operator-dependent variability. We present GlycanPRMQuant, an open-source Python pipeline that integrates precursor-glycan matching, fragment-level MS/MS annotation, automated isobaric conflict resolution via diagnostic fragment fingerprinting, and fragment-confirmed AUC quantification into a single reproducible workflow. The isobaric conflict-resolution step represents the primary algorithmic contribution. Competing assignments within a chromatographic feature are evaluated using a discriminative score constructed from specificity-weighted fragment intensity, effective distinct fragment support, fragment mass accuracy, chromatographic coherence, and calibrated precursor mass likelihood. Assignments are further validated by target-decoy competition with charge-aware decoy fragments and are reported only when they satisfy the fragment-evidence requirements, defeat their corresponding decoy, and meet the specified q-value threshold. Features lacking discriminating evidence are reported as ambiguous rather than assigned. Unlike Skyline-based workflows, which require per-glycan transition curation in GlycoWorkbench and manual peak boundary review, GlycanPRMQuant produces identification and quantitation outputs directly from mzML input with no user intervention, reducing processing time and eliminating a principal source of inter-analyst variability. Quantitative agreement with a manually curated Skyline reference yielded Pearson’s R of 0.992−1.000, with median CVs of 5.08% and 10.72% for bovine fetuin and ribonuclease B glycans across replicate injections.
No takes yet. Share an insight, caveat, or question.
Sandilya et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: